Premium
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D iseases
Author(s) -
GarciaPavia Pablo,
Rapezzi Claudio,
Adler Yehuda,
Arad Michael,
Basso Cristina,
Brucato Antonio,
Burazor Ivana,
Caforio Alida L.P.,
Damy Thibaud,
Eriksson Urs,
Fontana Marianna,
Gillmore Julian D.,
GonzalezLopez Esther,
Grogan Martha,
Heymans Stephane,
Imazio Massimo,
Kindermann Ingrid,
Kristen Arnt V.,
Maurer Mathew S.,
Merlini Giampaolo,
Pantazis Antonis,
Pankuweit Sabine,
Rigopoulos Angelos G.,
Linhart Ales
Publication year - 2021
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.2140
Subject(s) - medicine , cardiac amyloidosis , amyloidosis , position statement , cardiology , disease , heart failure , family medicine
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non‐invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non‐invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.